In the tissue cohort, CRC tissue enriched all of the pathways involved in the adenoma–carcinoma sequence, including WNT β-catenin, KRAS signaling, MTORC1, and TGF-β pathways (Figure 2A, Table S1; NES = −1.36 FDR = 0.184; NES = −1.57 FDR = 0.136; NES = −1.58 FDR = 0.150; NES = −1.30 FDR = 0.234, respectively). The gene discussed is KRAS; the disease is adenoma.